Besilesomab (trade name Scintimun) is a mouse monoclonal antibody labelled with the radioactive isotope technetium-99m.

SCINTIMUN has been used since 1992 mainly in Hungary, Czech Republic, and Switzerland on the basis of local marketing authorizations, and in Germany (on the basis of individual prescription).

In 2009, the EMEA has approved SCINTIMUN for marketing in all European countries.

[2][3] Immune activation: Dostarlimab Other: Ibalizumab

You can help Wikipedia by expanding it.This antineoplastic or immunomodulatory drug article is a stub.